Poland's medical cannabis market reached an estimated value of over 45 million euros in 2025 and has accumulated more than 105,000 registered patients, making it one of the fastest-growing import-dependent markets in Europe. Every gram dispensed in a Polish pharmacy is imported. Domestic cultivation exists in name only. A single research institution holds the only cultivation permit issued to date, and no commercial domestic production has reached supply chains as of 2026.
For Canadian Health Canada-licensed producers, that supply gap is both an opportunity and a caution: Poland is commercially significant, but the import pathway is built on pharmaceutical-grade compliance rather than trade agreements. Getting in means holding the right documentation, understanding the role of Poland's Chief Pharmaceutical Inspectorate (GIF), and working with a Polish importer who holds valid narcotic authorisation.
This guide covers what Canadian LPs need to know before entering the Polish medical cannabis market, from the regulatory framework that governs supply to the documentation Polish distributors will expect at the point of purchase.
How Poland's medical cannabis framework works
Medical cannabis in Poland sits under two primary statutes: the Act on Counteracting Drug Addiction of 29 July 2005 and the Pharmaceutical Law Act, with subordinate regulations issued by the Ministry of Health. The medicinal carve-out came into force on 1 November 2017, when an amendment classified herbal cannabis as a pharmaceutical raw material that may be dispensed in prescription preparations by licensed pharmacies.
Under this framework, any company that manufactures, processes, imports, or distributes medical cannabis in Poland must hold two separate authorisations:
- A standard business activity authorisation for the relevant pharmaceutical activity
- A narcotic authorisation issued by the Chief Pharmaceutical Inspectorate (Glowny Inspektorat Farmaceutyczny, GIF)
Products placed on the Polish market must also obtain a marketing authorisation, issued by the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). That process typically takes over two years, and authorisations last for five years once granted. Approximately 30 authorised flower products are currently available in Poland.
Prescriptions can be written by any physician authorised to prescribe narcotics. Most prescribers are specialists in neurology, oncology, or anaesthesiology, though general practitioners and cannabis clinics also participate. There is no reimbursement from the Polish public health system. Patients pay the full cost, which averaged approximately 47 PLN per gram in 2025.
One regulatory development worth tracking: in November 2024, Poland's Ministry of Health restricted telemedicine for initial cannabis consultations. Patients must now attend an in-person examination before receiving their first prescription. This change reduced patient inflow in the short term but has not materially affected import demand. Poland's annual import licence limit was set at 20 million grams in 2025, against actual dispensing of roughly 5,450 kg, leaving significant licensed headroom.
The import supply chain and Canada's role
Poland is entirely import-dependent for its medical cannabis supply. Two source countries dominate: Portugal and Canada. According to market data from early 2026, approximately 68% of authorised flower products come from Portugal and 32% from Canada. A significant share of the Portuguese volume consists of Canadian-origin cannabis that undergoes final processing or repackaging in Portugal before re-export, meaning Canada's actual contribution to Polish supply is higher than the direct import figure suggests.
Most products reaching Poland are packaged in Germany before being shipped onward. This reflects a well-established European distribution architecture in which German operators act as regional hubs for EU member states. For Canadian LPs, this creates two practical access routes:
Direct supply to a Polish narcotic-authorised importer. The Polish importer holds the narcotic authorisation and marketing authorisation for the product. They purchase directly from the Canadian LP under a supply agreement. The Canadian LP must hold an export permit under the Cannabis Act and the products must meet EU-GMP or EU-GMP-equivalent documentation standards.
Supply through a German distribution partner. The Canadian LP supplies a German-based importer or packager who holds EU distribution authorisation and manages onward supply to Poland and other EU member states. This route uses the German pharmaceutical distribution network but adds a layer of intermediary margin and logistics.
Either route requires the Canadian LP to hold valid export authorisation under the Cannabis Regulations and to supply a full documentation package that meets the standards the Polish importer will present to GIF for continued import approvals.
For context, Aurora Cannabis received Poland's first import permit from the Ministry of Health for a non-government cannabis company in an earlier supply cycle, shipping to a pain treatment centre and a hospital in Warsaw. The path they cleared demonstrated that Canadian-origin products can satisfy GIF requirements. The Polish importer's responsibility is to hold the permit; the Canadian LP's responsibility is to supply documentation that supports it. See our guide to how Canadian LPs export cannabis to Germany for comparison with a neighbouring EU market.
Documentation Polish importers expect from a Canadian LP
The Polish regulatory framework requires that imported cannabis meet pharmaceutical manufacturing standards. Your Polish distribution partner will need to present a documentation package to GIF demonstrating product quality, origin, and chain of custody. Below is what they need from you.
Certificate of Analysis (COA). Every batch must be accompanied by an ISO/IEC 17025-accredited COA covering, at minimum: cannabinoid potency (THC, CBD, CBN), moisture content, water activity, microbiological limits, residual solvents, heavy metals, mycotoxins, and pesticide residues. Polish pharmacies compound and dispense cannabis as a raw pharmaceutical material, so the COA serves as the primary quality document throughout the distribution chain. For guidance on how to structure batch COA data, see our COA guide for B2B buyers.
EU-GMP or equivalent documentation. Poland, as an EU member state, operates within the European Medicines Agency's manufacturing quality framework. Imported cannabis should be produced under EU-GMP-equivalent conditions, with a site master file (SMF) or quality dossier demonstrating manufacturing controls, SOPs, and audit history. Canadian LPs who have pursued EU-GMP certification hold a real advantage here. Those who have not should supply, at minimum, a gap analysis showing how their Health Canada GMP systems map to EU-GMP Annex requirements. Our article on EU-GMP vs Health Canada GMP for Canadian LPs covers that mapping in detail.
Health Canada manufacturing licence and export permit. The Polish importer will require confirmation that the Canadian LP holds a valid Standard Cultivation and/or Processing licence from Health Canada and has obtained the required export permit under the Cannabis Act. Export permits are batch-specific and issued by Health Canada's Office of Cannabis Management. See the Health Canada export permit process guide for step-by-step detail.
Phytosanitary certificate. Issued by the Canadian Food Inspection Agency (CFIA), this document certifies that the cannabis flower meets plant health requirements. It accompanies each shipment and is a standard requirement for plant-based pharmaceutical material crossing international borders.
Product specification sheet and packaging documentation. Polish importers building URPL marketing authorisation dossiers require detailed product specifications. If your product is entering under a new or renewed authorisation, the URPL application will require full labelling and packaging compliance documentation consistent with EU pharmaceutical standards.
If your batch records, testing data, and quality systems are well-organised, the documentation burden is manageable. A Polish partner will find out quickly when they are not. Polish pharmacies operate under direct pharmacy inspectorate oversight, and product quality inconsistencies get escalated.
The 4-stage Poland market entry path for Canadian LPs
The Canada-Poland Cannabis Compliance Path: 4 Stages
There is no shortcut to the Polish market. The authorisation process is deliberate and takes time. What you can control is how prepared you are when you engage a Polish distribution partner.
Stage 1: Validate your compliance baseline. Before approaching Polish importers, confirm that your documentation package is complete: current Health Canada licence, export permit history, ISO 17025-accredited COA template, EU-GMP gap documentation, phytosanitary procedures with CFIA, and a packaging and labelling specification that can be adapted for EU market requirements. Polish partners have seen enough Canadian suppliers to identify quickly whether a compliance foundation is real or approximate.
Stage 2: Identify and qualify a licensed Polish importer. Your Polish distribution partner must hold both a standard business authorisation and a narcotic authorisation from GIF. They must also hold, or be in the process of obtaining, a product marketing authorisation from URPL for your specific product. That authorisation process can take over two years. You are unlikely to see your first shipment to Poland within 12 months of starting this process unless your partner already holds an authorisation that can accommodate your product specifications.
Stage 3: Obtain the export permit from Health Canada. Each shipment requires a batch-specific export permit under the Cannabis Act. A corresponding import permit from the Polish competent authority is also required (your Polish importer handles the Polish side of this), but your paperwork must be ready before they can proceed. The INCB import/export permit system governs this process for Schedule I narcotics under the Single Convention on Narcotic Drugs.
Stage 4: Execute the first shipment and establish supply continuity. The first shipment to a new Polish partner is treated as a proof-of-compliance exercise by both GIF and your distribution partner. Documentation accuracy, batch consistency, and shipping compliance on the first order sets the tone for the relationship. LPs who treat the first shipment as a test order tend to build faster reorder cycles.
Frequently Asked Questions
AlphaLeaf is a Montreal-based Health Canada Licensed Producer of indoor-grown, hand-trimmed cannabis flower. Our export operations run under Cannabis Act authorisation, and we supply ISO/IEC 17025-certified COAs with full batch traceability on every shipment. For Polish importers building or expanding their product catalogue with Canadian-origin flower, our compliance documentation and cultivation records are built to support the GIF authorisation process from the first inquiry.
Does Canada export medical cannabis to Poland?
Yes. Canada is one of two primary source countries for Poland's medical cannabis supply, accounting for approximately 32% of authorised flower products on the market as of 2026. A significant share of Portuguese-labelled imports also consists of Canadian-origin cannabis processed or repackaged in Portugal before distribution into Poland and other EU member states.
What regulatory body governs medical cannabis imports in Poland?
Medical cannabis imports in Poland are regulated by the Chief Pharmaceutical Inspectorate (GIF), which issues narcotic authorisations to importers and distributors. Product marketing authorisations are issued separately by the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Both authorisations are required before a product can be placed on the Polish market.
Does a Canadian LP need EU-GMP certification to export to Poland?
EU-GMP certification is not a statutory requirement for Canadian LPs to export to Poland, but it materially accelerates the Polish importer's URPL authorisation process. LPs without full certification should supply a detailed gap analysis showing how their Health Canada GMP system maps to EU-GMP Annex requirements.
How long does it take to enter the Polish medical cannabis market?
The URPL marketing authorisation process typically takes over two years. If your Polish distribution partner already holds a marketing authorisation compatible with your product, the entry timeline shortens to the export permit and supply agreement process, which can take three to six months. The Health Canada export permit process for each shipment adds additional lead time per batch.
What documentation do Polish cannabis importers require from Canadian LPs?
Polish importers typically require: an ISO/IEC 17025-accredited certificate of analysis covering potency, microbiological limits, heavy metals, pesticides, and residual solvents; EU-GMP or equivalent manufacturing documentation; a valid Health Canada licence; a batch-specific export permit under the Cannabis Act; a phytosanitary certificate from the CFIA; and a detailed product specification and packaging compliance document.
Is the Polish medical cannabis market growing?
Yes. Poland's medical cannabis market was estimated at over 45 million euros in 2025 and has reached more than 105,000 registered patients. The annual import authorisation limit stood at 20 million grams in 2025, against actual dispensing of approximately 5,450 kg, indicating substantial licensed headroom for growth as patient numbers continue to expand.
